Karyopharm cuts FY2023 revenue guidance on higher patient assistance; Q1 net loss narrows

Karyopharm Therapeutics Inc.

2023-Q1 EPS reported -$0.30 revenue$38,698,000

Q1 total revenue $38.7M, XPOVIO net product revenue $28.3M flat YoY; net loss $34.1M ($0.30/sh) vs $41.4M loss YoY.
FY2023 total revenue guidance lowered to $145-160M (from $160-175M); XPOVIO net product revenue now $110-125M due to increased patient assistance programs.
Non-GAAP R&D and SG&A expense guidance reduced to $245-260M; cash runway reiterated to late 2025.
Phase 1 selinexor+ruxolitinib in front-line MF: 83.3% SVR35 at wk12, 80% TSS50; Phase 3 planned 1H 2023.
Eltanexor in Hr R/R MDS interim: median OS 8.7 months; UK marketing authorization granted for NEXPOVIO combo.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Karyopharm Therapeutics Inc. reported First Quarter 2023 results: revenue $38.7 Million.

Period: First Quarter 2023
Revenue: $38.7 Million
Result: reported results

Exact text from the filing

Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO ® (selinexor) Net Product Revenue of $28.3 Million, Adversely Impacted by Increased Utilization of Patient Assistant Programs (PAP) and Higher Gross to Net; YoY Growth in Total Demand 1

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Karyopharm Therapeutics Inc. reported Full Year 2023 results: revenue $145 Million to $160 Million. Guidance lowered.

Period: Full Year 2023
Revenue: $145 Million to $160 Million
Guidance: lowered
Result: guidance update

Exact text from the filing

Company Revises Full Year 2023 Total Revenue Guidance to $145 Million to $160 Million, Including Revised XPOVIO Net Product Revenue Guidance of $110 Million to $125 Million, Reflecting Increased Use of PAP – – Non-GAAP R&D and SG&A Expense Guidance Revised to $245 Million to $260 Million; Company Re-iterates Cash Runway to Late 2025

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-135082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.